1. Home
  2. MSLE vs MCRB Comparison

MSLE vs MCRB Comparison

Compare MSLE & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MSLE

Satellos Bioscience Inc. Common Stock

N/A

Current Price

$7.17

Market Cap

146.9M

Sector

N/A

ML Signal

N/A

Logo Seres Therapeutics Inc.

MCRB

Seres Therapeutics Inc.

HOLD

Current Price

$8.61

Market Cap

139.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MSLE
MCRB
Founded
N/A
2010
Country
Canada
United States
Employees
17
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
146.9M
139.7M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
MSLE
MCRB
Price
$7.17
$8.61
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$14.00
AVG Volume (30 Days)
103.3K
39.3K
Earning Date
N/A
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.64
Revenue
N/A
$789,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$13.41
Revenue Growth
N/A
N/A
52 Week Low
$5.50
$0.36
52 Week High
$13.39
$29.98

Technical Indicators

Market Signals
Indicator
MSLE
MCRB
Relative Strength Index (RSI) 47.74 43.92
Support Level $6.67 $7.98
Resistance Level $7.52 $9.53
Average True Range (ATR) 0.66 0.64
MACD 0.27 0.06
Stochastic Oscillator 83.65 28.88

Price Performance

Historical Comparison
MSLE
MCRB

About MSLE Satellos Bioscience Inc. Common Stock

Satellos Bioscience Inc is a regenerative medicine company a biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease.

About MCRB Seres Therapeutics Inc.

Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.

Share on Social Networks: